PI 3-Kinase/Akt Signaling
The PI 3-Kinase/Akt signaling pathway is involved in fundamental cellular processes including protein synthesis, proliferation and survival. PI 3-kinase is activated following ligand binding to a range of receptors such as integrin receptors, receptor tyrosine kinases, cytokine receptors and some 7-TM receptors.
PI 3-Kinase/Akt Signaling Target Files
PI 3-kinase promotes PIP3 formation, which translocates Akt to cell membranes and allows Akt activation through phosphorylation mediated by phosphoinositide dependent kinase 1 (PDK1). Akt mediates many of the downstream actions of PI 3-kinase, which include activation of mTOR and p70 S6K to promote protein synthesis, inhibition of Bad to attenuate the proapoptotic signal and regulation of neuronal functioning through interactions with GABAA receptors. Furthermore, Akt is a key regulator of insulin signaling and glucose metabolism.
Literature for PI 3-Kinase/Akt Signaling
Tocris offers the following scientific literature for PI 3-Kinase/Akt Signaling to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
RAS Oncoproteins Scientific Review
Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.
Pathways for PI 3-Kinase/Akt Signaling
Akt Signaling Pathway
The Akt signaling pathway plays a key role in the mediation of protein synthesis, metabolism, proliferation and cell cycle progression. It may be referred to as a 'prosurvival' pathway.
Our review provides a thorough overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutics vulnerabilities are explored with a detailed section on RAS drug discovery.
Request copyRequest PDF